VCEL Live signals | Maximize Profits with Getagraph.com

SELL 157816 min ago

@ $47.14

Issued: 14 Feb 2024 @ 12:51

Return: 1.19%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 5.65 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	180 290
Average Volume	399 765
Market Cap	2.32B
EPS	$0 ( 2024-05-08 )
Next earnings date	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	4 770.00
ATR14	$0.0500 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-20	Hopper Jonathan Mark	Buy	10 000	Common Stock
2024-05-20	Hopper Jonathan Mark	Sell	10 000	Common Stock
2024-05-20	Hopper Jonathan Mark	Buy	10 000	Stock Option (Right to Buy)
2024-05-17	Halpin Michael	Buy	3 132	Common Stock
2024-05-17	Halpin Michael	Buy	2 063	Common Stock

INSIDER POWER
71.47
Last 100 transactions
Buy: 927 291 \| Sell: 149 747

Volume Correlation

Long: 0.21 (neutral)

Short: 0.08 (neutral)

Signal:(59.835) Neutral

Vericel Corp Correlation

10 Most Positive Correlations
ADTH	0.89
KBWP	0.878
INBK	0.872
KRUS	0.87
AGNCP	0.868
OGI	0.865
DKNG	0.862
MSFT	0.859
AGNCO	0.856
SILK	0.855

10 Most Negative Correlations
PLL	-0.911
IRBT	-0.897
SGML	-0.897
MRCY	-0.895
WINT	-0.891
PRSO	-0.891
RDHL	-0.887
ALTM	-0.885
REVB	-0.88
IMMX	-0.879

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vericel Corp Correlation - Currency/Commodity

-0.34
( neutral )

0.20
( neutral )

0.00
( neutral )

-0.53
( weak negative )

-0.07
( neutral )

-0.27
( neutral )

Vericel Corp Financials

Annual	2023
Revenue:	$197.52M
Gross Profit:	$135.58M (68.64 %)
EPS:	$-0.0669

FY	2023
Revenue:	$197.52M
Gross Profit:	$135.58M (68.64 %)
EPS:	$-0.0669

FY	2022
Revenue:	$164.37M
Gross Profit:	$109.79M (66.80 %)
EPS:	$-0.350

FY	2021
Revenue:	$156.18M
Gross Profit:	$106.03M (67.88 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Vericel Corp Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Vericel Corp

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.